Published in Am J Gastroenterol on March 03, 2015
Fecal Calprotectin Level in Patients With Nosocomial Diarrhea | NCT04491799
Irritable bowel syndrome. Nat Rev Dis Prim (2016) 1.14
Utility of Fecal Markers to Diagnose and Monitor Inflammatory Bowel Diseases. Am J Gastroenterol (2015) 1.07
The utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS. Am J Gastroenterol (2015) 1.05
New and Emerging Treatment Options for Irritable Bowel Syndrome. Gastroenterol Hepatol (N Y) (2015) 0.91
Irritable bowel syndrome and inflammatory bowel disease overlap syndrome: pieces of the puzzle are falling into place. Intest Res (2016) 0.82
Overlapping irritable bowel syndrome and inflammatory bowel disease: less to this than meets the eye? Therap Adv Gastroenterol (2016) 0.81
Use of blood based biomarkers in the evaluation of Crohn's disease and ulcerative colitis. World J Gastrointest Endosc (2015) 0.79
Comparison of Symptoms, Healthcare Utilization, and Treatment in Diagnosed and Undiagnosed Individuals With Diarrhea-Predominant Irritable Bowel Syndrome. Am J Gastroenterol (2017) 0.79
Fecal calprotectin: its scope and utility in the management of inflammatory bowel disease. J Gastroenterol (2016) 0.79
Advances in IBS 2016: A Review of Current and Emerging Data. Gastroenterol Hepatol (N Y) (2016) 0.78
Enhancing High Value Care in Gastroenterology Practice. Clin Gastroenterol Hepatol (2016) 0.77
Point of Care Ultrasound Accurately Distinguishes Inflammatory from Noninflammatory Disease in Patients Presenting with Abdominal Pain and Diarrhea. Can J Gastroenterol Hepatol (2016) 0.76
Emerging role of novel biomarkers in the diagnosis of inflammatory bowel disease. World J Gastrointest Pharmacol Ther (2016) 0.75
Capsule endoscopy for the diagnosis and follow up of Crohn's disease: a comprehensive review of current status. Ann Gastroenterol (2016) 0.75
Relevance of fecal calprotectin and lactoferrin in the post-operative management of inflammatory bowel diseases. World J Gastrointest Surg (2016) 0.75
Endoscopy and cross-sectional imaging for assessing Crohn׳s disease activity. Tech Gastrointest Endosc (2016) 0.75
Response to Dai et al. Am J Gastroenterol (2015) 0.75
Update on clinical and research application of fecal biomarkers for gastrointestinal diseases. World J Gastrointest Pharmacol Ther (2017) 0.75
Faecal biomarker patterns in patients with symptoms of irritable bowel syndrome. Frontline Gastroenterol (2016) 0.75
Elevated fecal calprotectin levels during necrotizing enterocolitis are associated with activated neutrophils extruding neutrophil extracellular traps. J Perinatol (2016) 0.75
Reducing inappropriate ESR testing with computerized clinical decision support. BMJ Qual Improv Rep (2016) 0.75
New Biomarkers for Diagnosing Inflammatory Bowel Disease and Assessing Treatment Outcomes. Inflamm Bowel Dis (2016) 0.75
Response to Sorrentino et al. Am J Gastroenterol (2015) 0.75
Gender Differences in Serotonin Signaling in Patients with Diarrhea-predominant Irritable Bowel Syndrome. Intern Med (2017) 0.75
The impact of panenteric capsule endoscopy on the management of Crohn's disease. Therap Adv Gastroenterol (2017) 0.75
Updates to the Rome Criteria for Irritable Bowel Syndrome. Gastroenterol Hepatol (N Y) (2017) 0.75
Diagnostic Value of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Crohn's Disease. Gastroenterol Res Pract (2017) 0.75
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med (2009) 35.37
Functional bowel disorders. Gastroenterology (2006) 20.72
The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol (2003) 16.17
Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology (2004) 14.78
The burden of selected digestive diseases in the United States. Gastroenterology (2002) 6.79
AGA technical review on irritable bowel syndrome. Gastroenterology (2002) 6.76
Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. BMJ (2010) 4.69
An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol (2009) 3.99
Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease. Gastroenterology (2002) 3.08
Role of faecal calprotectin as non-invasive marker of intestinal inflammation. Dig Liver Dis (2003) 2.79
A simple method for assessing intestinal inflammation in Crohn's disease. Gut (2000) 2.69
Serum levels of C-reactive protein in Crohn's disease and ulcerative colitis. Eur J Clin Invest (1982) 2.48
Prevalence of symptoms meeting criteria for irritable bowel syndrome in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol (2012) 2.46
Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. Am J Gastroenterol (2007) 2.39
Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal malignancy. Am J Gastroenterol (2007) 2.38
The yield of colonoscopy in patients with non-constipated irritable bowel syndrome: results from a prospective, controlled US trial. Am J Gastroenterol (2010) 2.30
Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings. Inflamm Bowel Dis (2008) 2.22
Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol (2009) 2.16
Is irritable bowel syndrome a diagnosis of exclusion?: a survey of primary care providers, gastroenterologists, and IBS experts. Am J Gastroenterol (2010) 2.02
Alterations in expression of p11 and SERT in mucosal biopsy specimens of patients with irritable bowel syndrome. Gastroenterology (2006) 1.91
Elevated human beta-defensin-2 levels indicate an activation of the innate immune system in patients with irritable bowel syndrome. Am J Gastroenterol (2009) 1.88
Fecal lactoferrin in discriminating inflammatory bowel disease from irritable bowel syndrome: a diagnostic meta-analysis. BMC Gastroenterol (2014) 1.82
Identification of a prodromal period in Crohn's disease but not ulcerative colitis. Am J Gastroenterol (2000) 1.77
The utility of diagnostic tests in irritable bowel syndrome patients: a systematic review. Am J Gastroenterol (2002) 1.67
Discriminating IBD from IBS: comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies. Inflamm Bowel Dis (2008) 1.65
An overlooked indicator of disease activity in ulcerative colitis: mean platelet volume. Platelets (2009) 1.56
S100A expression and interleukin-10 polymorphisms are associated with ulcerative colitis and diarrhea predominant irritable bowel syndrome. Dig Dis Sci (2013) 1.52
Fecal calprotectin more accurately reflects endoscopic activity of ulcerative colitis than the Lichtiger Index, C-reactive protein, platelets, hemoglobin, and blood leukocytes. Inflamm Bowel Dis (2013) 1.51
Diagnostic accuracy of fecal calprotectin assay in distinguishing organic causes of chronic diarrhea from irritable bowel syndrome: a prospective study in adults and children. Clin Chem (2003) 1.50
Calprotectin and lactoferrin in the assessment of intestinal inflammation and organic disease. Int J Colorectal Dis (2006) 1.44
Differing acute phase responses in Crohn's disease and ulcerative colitis. Gut (1986) 1.44
Epidemiology of IBS. Gastroenterol Clin North Am (2011) 1.42
Prospective evaluation of faecal neutrophil-derived proteins in identifying intestinal inflammation: combination of parameters does not improve diagnostic accuracy of calprotectin. Aliment Pharmacol Ther (2007) 1.29
Accuracy of four fecal assays in the diagnosis of colitis. Dis Colon Rectum (2007) 1.27
C-reactive protein as an aid in the differentiation of functional and inflammatory bowel disorders. Clin Chim Acta (1985) 1.22
Faecal lactoferrin--a novel test to differentiate between the irritable and inflamed bowel? Aliment Pharmacol Ther (2010) 1.18
Neutrophil gelatinase-associated lipocalin (NGAL) in inflammatory bowel disease: association with pathophysiology of inflammation, established markers, and disease activity. J Gastroenterol (2011) 1.06
Validation of a point-of-care desk top device to quantitate fecal calprotectin and distinguish inflammatory bowel disease from irritable bowel syndrome. J Crohns Colitis (2011) 1.06
Endothelial function and cardiovascular risk in active inflammatory bowel diseases. J Crohns Colitis (2013) 1.04
Fecal assays detect hypersensitivity to cow's milk protein and gluten in adults with irritable bowel syndrome. Clin Gastroenterol Hepatol (2011) 1.00
Diagnostic accuracy of faecal calprotectin estimation in prediction of abnormal small bowel radiology. Aliment Pharmacol Ther (2004) 0.99
Risk of inflammatory bowel disease following a diagnosis of irritable bowel syndrome. BMC Gastroenterol (2012) 0.97
Faecal calprotectin: a new marker for Crohn's disease? Ann Clin Biochem (2004) 0.96
The value of fecal calprotectin as a marker of intestinal inflammation in patients with ulcerative colitis. Turk J Gastroenterol (2012) 0.88
Irritable bowel syndrome: toward a cost-effective management approach. Am J Manag Care (2001) 0.87
Clinical utility of the assessment of fecal calprotectin in Leśniowski-Crohn's disease. Pol Arch Med Wewn (2008) 0.86
Lipid peroxidation markers in Crohn's disease: the associations and diagnostic value. Clin Chem Lab Med (2012) 0.83
Fecal chromogranins and secretogranins are increased in patients with ulcerative colitis but are not associated with disease activity. J Crohns Colitis (2013) 0.80
[Fecal calprotectin in differential diagnosis of irritable bowel syndrome]. Beijing Da Xue Xue Bao (2006) 0.78
The impact of bowel cleansing on follow-up recommendations in average-risk patients with a normal colonoscopy. Am J Gastroenterol (2014) 2.20
The impact of fair colonoscopy preparation on colonoscopy use and adenoma miss rates in patients undergoing outpatient colonoscopy. Gastrointest Endosc (2013) 1.67
ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Am J Gastroenterol (2017) 1.11
Patient compliance and suboptimal bowel preparation with split-dose bowel regimen in average-risk screening colonoscopy. Gastrointest Endosc (2014) 0.84
A Randomized Controlled Trial Comparing the Low FODMAP Diet vs. Modified NICE Guidelines in US Adults with IBS-D. Am J Gastroenterol (2016) 0.82
How Do US Gastroenterologists Use Over-the-Counter and Prescription Medications in Patients With Gastroesophageal Reflux and Chronic Constipation? Am J Gastroenterol (2015) 0.76
Response to Dai et al. Am J Gastroenterol (2015) 0.75
Response to Sorrentino et al. Am J Gastroenterol (2015) 0.75
The Light Shines on: American Journal of Gastroenterology 2015. Am J Gastroenterol (2015) 0.75
Response to Georgopoulos et al. Am J Gastroenterol (2017) 0.75
Introduction. J Gastroenterol Hepatol (2017) 0.75